优化尼沃卢马布的有效性:在高级非小细胞肺癌中剂量时间的作用
1Department of Internal Medicine, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Turkey.
概括
在下午1点之前给予尼沃卢马布免疫疗法可能会改善肺癌治疗反应. 较早的管理表明,在非小细胞肺癌患者中有望获得更好的结果,这需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 时间生物学 时间生物学
背景情况:
- 免疫疗法,包括尼沃卢马布,已推进肺癌治疗,但作为二线单一疗法的有效性有限.
- 研究影响免疫疗法反应的因素对于改善非小细胞肺癌 (NSCLC) 的结果至关重要.
研究的目的:
- 评估nivolumab的时间 (下午1点前或下午1点后) 是否影响二线NSCLC的治疗疗效.
- 探索慢性治疗在克服免疫疗法耐药性的潜力.
主要方法:
- 54名接受二线尼沃卢马布治疗的IV期或复发性NSCLC患者的回顾性分析.
- 根据给药时间分组患者:下午1点前或下午1点后.
- 两组之间的治疗反应,无进展生存率和与免疫相关的不良影响的比较.
主要成果:
- 在下午1点之前接受尼沃卢马布的患者表现出显著改善的治疗反应率.
- 两组之间没有观察到无进展生存时间的显著差异.
- 免疫相关的不良反应并没有根据服用时间有显著差异.
结论:
- 尼沃卢马布的服用时间可能会影响NSCLC的治疗结果,早期服用可能会增强反应.
- 这些发现支持昼夜节律在癌症治疗有效性中的作用.
- 需要进一步的前性研究来证实这些结果,并探索优化免疫治疗策略的潜在机制.
更多相关视频
相关概念视频
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
217
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
217
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
198
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
198
Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133
Rational Dosage Regimen: Maintenance Dose and Loading Dose
5.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.2K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
192
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
192
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


